Moderna’s Market Value Soars on Promising Cancer Vaccine Trial
A single trial readout has effectively doubled Moderna’s market capitalization in one trading session, with AI firm Perplexity predicting the upward rerating of the stock will continue. Perplexity forecasts Moderna’s share price could reach between $180 and $240 by the end of 2026, with a bullish base case scenario of $210.
Intisemran: The Key Driver for Moderna’s Valuation
The primary catalyst for this significant valuation shift is Intisemran, Moderna’s personalized mRNA cancer vaccine. Perplexity identifies it as the dominant factor influencing the company’s future valuation. The Phase 3 INTerpath-001 trial for melanoma met both of its primary endpoints, demonstrating improved recurrence-free survival and distant-metastasis-free survival when used in conjunction with Keytruda. This marks the first late-stage validation of Moderna’s oncology platform and Perplexity suggests it could unlock a substantial opportunity within the melanoma market.
Near-Term Catalysts Bolster the Outlook
Two immediate factors are also supporting the positive outlook for Moderna. The anticipated FDA approval of mFLUSIVA is expected to introduce a commercial product generating revenue before the oncology platform fully matures. Furthermore, revised cost guidance for 2026 suggests an improvement in cash-burn expectations. These developments are seen as providing crucial time for the oncology thesis to fully develop.
Risks Remain Data-Dependent
Despite the positive momentum, significant risks persist, primarily tied to future data. Disappointing hazard ratios are a key concern, followed by overall survival data, pricing strategies, and regulatory approval timelines. Any negative developments in these areas could potentially drive the stock price down to the $125 to $150 range.
Chart Analysis Reveals Dramatic Reversal
Technical analysis of Moderna’s daily chart illustrates a dramatic reversal following a four-year decline. The stock, which peaked near $170 in mid-2024, entered a prolonged downturn, plummeting from $120 to approximately $23 by late 2025. A base was established in the autumn of that year.
The recovery began in early 2026, pushing prices towards $60 by March. A surge to $85 occurred in July, followed by a pullback. The most recent trading session saw a significant surge, with the stock gapping up from $116 to close at $174.38 following the trial news.
The closing price of $174.38 represented a 176.97% increase, or $111.42. The daily trading range spanned from $114.46 to $176.66, with post-market trading reaching $180.17. Key support levels are identified at $150, $120, and $85, while resistance is anticipated at $180, $210, and $240.
The Relative Strength Index (RSI) stands at an exceptionally high 92.21, with its signal line lagging significantly at 52.98. This substantial gap of nearly 40 points indicates a one-day repricing event rather than a sustained trend. The oscillator is deeply overbought, signaling extreme momentum that rarely persists without a period of consolidation.
Perplexity’s base case scenario places the stock 20% higher than its current close. The market’s ability to sustain this new valuation will hinge on detailed efficacy data and ongoing regulatory discussions.
Moderna’s 177% surge serves as a stark reminder that markets often await a single, decisive event to resolve uncertainty.
Leave a Reply